Endothelin-1 as a biomarker of idiopathic pulmonary fibrosis and interstitial lung disease associated with autoimmune diseases

The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD assoc...

Descripción completa

Detalles Bibliográficos
Autores: Pulito-Cueto, Verónica, Genre, Fernanda, López-Mejías, Raquel, Mora Cuesta, Víctor Manuel|||0000-0002-8161-0462, Iturbe Fernández, David|||0000-0002-5241-266X, Portilla González, Virginia, Sebastián Mora-Gil, María, Ocejo-Vinyals, Javier Gonzalo, Gualillo, Oreste, Blanco Alonso, Ricardo|||0000-0003-2344-2285, Corrales Martínez, Alfonso, Ferraz-Amaro, Iván, Castañeda, Santos, Cifrián Martínez, José Manuel, Atienza Mateo, Belén, Remuzgo-Martínez, Sara, González-Gay Mantecón, Miguel Ángel
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universidad de Cantabria (UC)
Repositorio:UCrea Repositorio Abierto de la Universidad de Cantabria
Idioma:inglés
OAI Identifier:oai:repositorio.unican.es:10902/29873
Acceso en línea:https://hdl.handle.net/10902/29873
Access Level:acceso abierto
Palabra clave:Interstitial lung disease
Idiopathic pulmonary fibrosis
Interstitial lung disease associated with autoimmune diseases
Biomarker
Endothelin-1
Descripción
Sumario:The aim of this study was to determine the role of endothelin-1 (ET-1), a molecule involved in multiple vascular and fibrosing abnormalities, as a biomarker of interstitial lung disease (ILD), as well as its use for the differential diagnosis between idiopathic pulmonary fibrosis (IPF) and ILD associated with autoimmune diseases (AD-ILD), using a large and well-defined cohort of patients with ILD. A total of 112 patients with IPF, 91 patients with AD-ILD (28 rheumatoid arthritis (RA), 26 systemic sclerosis, 20 idiopathic inflammatory myositis and 17 interstitial pneumonia with autoimmune features) and 44 healthy controls were included. ET-1 serum levels were determined by enzyme-linked immunosorbent assay. A significant increase in ET-1 levels was found in patients with IPF compared to controls. Likewise, AD-ILD patients also showed higher ET-1 levels than controls when the whole cohort was stratified by the type of AD. Similar ET-1 levels were found in IPF and AD-ILD patients, regardless of the underlying AD. Interestingly, increased ET-1 levels were correlated with worse lung function in IPF and RA-ILD patients. Our study supports that serum ET-1 may be useful as a biomarker of ILD, although it could not help in the differential diagnosis between IPF and AD-ILD. Moreover, ET-1 levels may be associated with ILD severity.

Similares en LA Referencia